The Principal Investment team targets investments in well-established life science companies with leading positions in attractive market segments and strong underlying growth drivers. We provide access to evergreen funds across the entire capital structure.
In addition to capital and engagement, an investment from Novo Holdings also provides access to our extensive network within the life science industry. We use our experience and expertise from our ownership of world-leading life science companies to actively support a board and management in realizing their strategic ambitions.
At the end of 2020, the Principal Investments portfolio comprised 12 companies, with a total value of EUR 8 billion.